Vor Biopharma Inc.
VORAs of the close on Sep 25, 2026
Price
$18.52
Market cap
$1.1B
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Vor Biopharma Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 12, 2026. The latest institutional report shown is dated Sep 30, 2025; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| JOHNSON & JOHNSON | 2025-09-30 | 53,732 | Not shown | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2025-06-30 | 1,017 | Not shown | SEC filing |
| JANE STREET GROUP, LLC | 2025-06-30 | 525,613 | Not shown | SEC filing |
| STATE STREET CORP | 2025-06-30 | 115,934 | Not shown | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2025-06-30 | 169,636 | Not shown | SEC filing |
| Chicago Partners Investment Group LLC | 2025-06-30 | 10,887 | Not shown | SEC filing |
| VANGUARD GROUP INC | 2025-06-30 | 1,915,606 | Not shown | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2025-06-30 | 468,112 | Not shown | SEC filing |
| Allworth Financial LP | 2025-06-30 | 60 | Not shown | SEC filing |
| UBS Group AG | 2025-06-30 | 1,531,636 | Not shown | SEC filing |
| MORGAN STANLEY | 2025-06-30 | 503 | Not shown | SEC filing |
| Tower Research Capital LLC (TRC) | 2025-06-30 | 2,295 | Not shown | SEC filing |
| Trustees of Columbia University in the City of New York | 2025-06-30 | 91,910 | Not shown | SEC filing |
| Bollard Group LLC | 2025-06-30 | 55,555 | Not shown | SEC filing |
| BlackRock, Inc. | 2025-06-30 | 374,763 | Not shown | SEC filing |
| SBI Securities Co., Ltd. | 2025-06-30 | 400 | Not shown | SEC filing |
| GOLDMAN SACHS GROUP INC | 2025-06-30 | 180,788 | Not shown | SEC filing |
| MAI Capital Management | 2025-06-30 | 3,652 | Not shown | SEC filing |
- Each value is checked against Vor Biopharma Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: no share price from within three months of its report date is on file, so it could not be checked.
- Value not shown for 17 rows: the value per share could not be confirmed against the share prices on file from within three months of the report date.
- 2 rows left out: the value per share they report is far from Vor Biopharma Inc.'s share prices on file from around the report date, far from the value most filers reported for that date, or the value of a security already left out, so they may describe another security or share class.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security. Filers with a row left out above, or with no row above to check, are not listed.
- JOHNSON & JOHNSON: 1,074,658 shares reported 2025-06-30; 53,732 shares reported 2025-09-30.
- JOHNSON & JOHNSON: 1,074,658 shares reported 2025-03-31; 1,074,658 shares reported 2025-06-30.
- MAI Capital Management: 288,363 shares reported 2025-03-31; 3,652 shares reported 2025-06-30.
- SBI Securities Co., Ltd.: 133 shares reported 2025-03-31; 400 shares reported 2025-06-30.
- BlackRock, Inc.: 484,506 shares reported 2025-03-31; 374,763 shares reported 2025-06-30.
- Bollard Group LLC: 55,555 shares reported 2025-03-31; 55,555 shares reported 2025-06-30.
- Trustees of Columbia University in the City of New York: 91,910 shares reported 2025-03-31; 91,910 shares reported 2025-06-30.
- Tower Research Capital LLC (TRC): 3,448 shares reported 2025-03-31; 2,295 shares reported 2025-06-30.
- MORGAN STANLEY: 35,441 shares reported 2025-03-31; 503 shares reported 2025-06-30.
- UBS Group AG: 8,455 shares reported 2025-03-31; 1,531,636 shares reported 2025-06-30.
- RENAISSANCE TECHNOLOGIES LLC: 701,431 shares reported 2025-03-31; 468,112 shares reported 2025-06-30.
- VANGUARD GROUP INC: 1,940,223 shares reported 2025-03-31; 1,915,606 shares reported 2025-06-30.
Showing the 12 most recent filer reports.
29 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Vor Biopharma Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-04-17 · RA Capital Healthcare Fund LP: Larger than 82 of the 88 other insider sales of Common Stock on file. SEC filing
- 2026-04-13 · RA Capital Healthcare Fund LP: Larger than 84 of the 88 other insider sales of Common Stock on file. SEC filing
- 2026-04-06 · RA Capital Healthcare Fund LP: Larger than 85 of the 88 other insider sales of Common Stock on file. SEC filing
- 2025-09-09 · Hoffman Reid: Larger than 80 of the 88 other insider sales of Common Stock on file. SEC filing
- 2025-09-08 · Hoffman Reid: Larger than 83 of the 88 other insider sales of Common Stock on file. SEC filing
- 2025-09-04 · Hoffman Reid: Larger than 81 of the 88 other insider sales of Common Stock on file. SEC filing
- 2025-09-03 · Hoffman Reid: Larger than 86 of the 88 other insider sales of Common Stock on file. SEC filing
- 2025-08-28 · Hoffman Reid: Larger than all 88 other insider sales of Common Stock on file. SEC filing
- 2025-08-27 · Hoffman Reid: Larger than 87 of the 88 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-04-22 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | S — Open market or private sale | −165,150 | 15.77 | SEC filing |
| 2026-04-20 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | S — Open market or private sale | −171,963 | 15.77 | SEC filing |
| 2026-04-17 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | S — Open market or private sale | −458,411 | 16.28 | SEC filing |
| 2026-04-15 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | S — Open market or private sale | −53,644 | 16.01 | SEC filing |
| 2026-04-14 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | S — Open market or private sale | −153,735 | 15.97 | SEC filing |
| 2026-04-13 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | S — Open market or private sale | −530,610 | 16.15 | SEC filing |
| 2026-04-10 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | S — Open market or private sale | −828 | 15.75 | SEC filing |
| 2026-04-09 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | S — Open market or private sale | −135,201 | 16.59 | SEC filing |
Showing 8 of 12 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-11 | Beckman Daniella · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +53,283 | SEC filing |
| 2026-06-11 | RA Capital Healthcare Fund LP · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +57,162 | SEC filing |
| 2026-06-11 | Namouni Fouad · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +56,549 | SEC filing |
| 2026-06-11 | Kalir Erez · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +57,162 | SEC filing |
| 2026-06-11 | Cumbo Alexander · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +56,345 | SEC filing |
| 2026-06-11 | Levin Andrew David · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +57,162 | SEC filing |
| 2026-06-11 | Detheux Michel · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +57,162 | SEC filing |
| 2026-06-11 | Joustra Wouter · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +57,162 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-12-05 | Mahatme Sandesh · CFO | Common Stock | D — Disposition to the issuer | −694,137 | SEC filing |
| 2025-12-05 | Kress Jean-Paul · CEO and Chairman | Employee Stock Option (right to buy) | D — Disposition to the issuer | −4,164,831 | SEC filing |
| 2025-12-05 | Zuraw Qing Che · Chief Development Officer | Employee Stock Option (right to buy) | D — Disposition to the issuer | −218,652 | SEC filing |
| 2025-02-03 | Chakraborty Tirtha · CHIEF SCIENTIFIC OFFICER | Employee Stock Option (right to buy) | D — Disposition to the issuer | −107,500 | SEC filing |
| 2025-02-03 | Chakraborty Tirtha · CHIEF SCIENTIFIC OFFICER | Employee Stock Option (right to buy) | D — Disposition to the issuer | −121,323 | SEC filing |
| 2025-02-03 | Chakraborty Tirtha · CHIEF SCIENTIFIC OFFICER | Employee Stock Option (right to buy) | D — Disposition to the issuer | −95,500 | SEC filing |
| 2025-02-03 | ANG ROBERT · PRESIDENT AND CEO | Employee Stock Option (right to buy) | D — Disposition to the issuer | −172,500 | SEC filing |
| 2025-02-03 | Attar Eyal C. · CHIEF MEDICAL OFFICER | Employee Stock Option (right to buy) | D — Disposition to the issuer | −364,000 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.